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ABSTRACT
Rationale: The 2016 guidelines for hospital-acquired pneumonia (HAP) suggest 
applying a universal antibiogram resistance threshold in addition to patient criteria 
to determine empiric coverage. The impact of these recommendations is unknown.
Objectives: 1) Describe national antibiotic use and microbiology patterns for HAP 
among patients with non-infectious admissions, 2) measure the predictive 
performance of the antibiogram threshold and risk factors, and 3) estimate the 
change in practice with guideline implementation. 
Methods: We conducted a retrospective analysis of all hospitalizations without 
initial infection but with secondary pneumonia diagnoses at Veterans Affairs Medical
Centers between 10/1/2012 and 9/30/2015. For each hospitalization we extracted: 
presence of MRSA and resistant GNR (R-GNR) in cultures, anti-MRSA and anti-
pseudomonal antimicrobial administration, and facility-level prevalence of MRSA 
and R-GNR. We calculated the percent hospitalizations with resistant organisms, 
broad-spectrum antibiotics, and the predictive performance of patient 
characteristics and prevalence thresholds for MRSA.
Measurements and Main Results: Among 3,562 cases, 5.17% were positive for 
MRSA and 2.30% for R-GNR. The recommended MRSA prevalence threshold was 
100.00% sensitive (95% confidence interval[CI], 98.02–100.00%) and 0.03% specific
(95% CI,0.00–0.16%) for MRSA-positive culture, leading to overtreatment of 94.81% 
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(95% CI,94.02-95.50%) of patients. Pressor order (odds ratio[OR] 3.89; 95% CI,1.17–
12.91) and IV antibiotics within the past 90 days (OR,1.98; 95% CI,1.03–3.81) were 
associated with MRSA. Mechanical ventilation was associated with R-GNR (OR,4.37; 
95% CI,1.52–12.57).
Conclusions: The guideline-recommended antibiogram threshold and 
characteristics did not improve prediction of MRSA or R-GNR and would have led to 
an increase in MRSA treatment.  
Abstract word count: 249
INTRODUCTION
Hospital-acquired pneumonia (HAP) is a common nosocomial infection with 
high mortality and an association with resistant bacteria.(1-6) Antimicrobial therapy,
including empiric therapy with activity against resistant organisms, should be 
tailored to individual patients, but the magnitude of risk for resistant infections is 
largely unknown.(6-13) Recent guidelines from the American Thoracic Society (ATS) 
and Infectious Disease Society of America (IDSA) for the diagnosis and management
of HAP provide recommendations for empiric antimicrobial selection based on 
perceived risk factors for resistant infections. They strongly recommend that each 
hospital generate antibiograms and provide thresholds for the proportion of 
resistance that would indicate need for coverage of methicillin-resistant 
Staphylococcus aureus (MRSA). Specifically, for HAP, coverage for MRSA is 
recommended if prevalence of resistance is >20% or unknown.(4, 14) MRSA 
coverage and 2 anti-pseudomonals are also recommended if the patient has 
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received prior intravenous antibiotics in the preceding 90 days, is in shock or 
requires ventilatory support. These guidelines were intended to “minimize patient 
harm and exposure to unnecessary antibiotics and reduce the development of 
antibiotic resistance”.(4) However, the implications of these guidelines for antibiotic
use are unknown, as is the prevalence of resistance nationally. 
Using a large national database we sought to 1) describe existing national 
practice and microbiology patterns prior to the guidelines, including the frequency 
of initial treatment for multi-drug resistant organisms and culture methods for HAP; 
2) measure the predictive performance of the specified risk factors and antibiogram
resistance threshold to identify patients with resistant organisms; and 3) estimate 
the change in practice with guideline implementation.
METHODS
Setting and Subject Selection
We conducted a retrospective analysis of HAP across all Veterans Affairs 
Medical Centers (VAMCs). We included all patients admitted between October 1, 
2012 and September 30, 2015 admitted to acute-care medical or surgical wards, an
observation unit, or an intensive care unit, with a non-principal diagnosis of 
pneumonia by ICD-9 (481- 486). We ended our sample period in 2015 to avoid the 
effect of change between ICD-9-CM and ICD-10-CM. We then limited our sample to 
non-infectious admissions by excluding those with a principal diagnosis of 
pneumonia, respiratory distress, or sepsis (507.0, 518.81, 518.84, 799.1, 785.52, 
995.91, 995.92) and those who received antibiotics or cultures within the first 48 
hours in order to improve our ability to specifically identify HAP (Figure 1). These 
were excluded because although HAP can occur after an infection present on 
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admission, retaining these admissions could lead to frequent misclassification of 
community-acquired pneumonia as HAP. Timing of infection was defined as the date
of earliest cultures or antibiotics. We validated the precision of our approach 
through chart review of 100 charts. 
In an effort to ensure the internal validity of our study, we initially limited our 
cohort of HAP patients to those who did not receive antibiotics or cultures during 
the first 48 hours of admission. To explore the generalizability of our findings we 
subsequently completed a sensitivity analysis among all  patients with a secondary 
diagnosis of pneumonia including those who received antibiotics or cultures in the 
initial 48 hours (Figure 1).
Data was accessed and analyzed using Veterans Informatics and Computing 
Infrastructure (VINCI).(15) 
Patient-level Measurements
After identifying our cohort of HAP patients, we then evaluated the following 
patient characteristics: age, sex, admission service, ICU admission, orders for 
vasopressors, average length of stay, thirty-day mortality, and presence of 
comorbid disease, including: cerebrovascular disease, congestive heart failure, 
diabetes, renal disease, and neoplastic disease. Next, we measured the percent of 
HAP patients who received empiric antimicrobial agents with activity against MRSA 
and two-drug therapy for resistant Gram-negative rods (R-GNR) as recommended in
the 2016 ATS/IDSA guidelines for HAP.(4)  For MRSA the suggested agents were: 
vancomycin and linezolid. For R-GNR the suggested agents were: piperacillin-
tazobactam, cefepime, ceftazidime, imipenem, meropenem, aztreonam, 
ciprofloxacin, levofloxacin, amikacin, gentamicin, tobramycin, colistin, and 
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polymyxin B. Of note, Veteran Affairs  pharmacy benefits management leaves all 
decisions regarding which antibiotics to carry to the local hospital or station. They 
state that these decisions should be based on local culture and sensitivity patterns. 
Additionally, we focused on the number of anti-pseudomonals being used to 
evaluate concern for resistance by the provider in an effort to accommodate 
prescribing practices. We also measured the percent hospitalizations that had blood
and respiratory cultures obtained at time of treatment. We measured the percent of
hospitalizations in which cultures detected MRSA and GNR resistant to piperacillin-
tazobactam. Nasal MRSA PCR screening data were not included in the estimates of 
resistance prevalence.
Antibiogram Development Feasibility and Application to HAP Cohort
We extracted all inpatient culture data from all VAMCs between 2011 and 
2014 to determine the ability of hospitals to generate antibiograms by location 
(hospital-wide vs ICU) and culture type (respiratory vs all). We defined a hospital’s 
ability to generate an antibiogram as the presence of ≥ 30 cultures during the year 
prior to the pneumonia.(16) For each facility we measured the ability to develop the
following antibiograms in 2014: hospital wide S. aureus resistance among all 
cultures, hospital wide S. aureus resistance among respiratory samples only, ICU-
level S. aureus resistance among all cultures, ICU-level S. aureus resistance among 
respiratory samples, ICU-level GNR resistance among all cultures, and ICU-level GNR
resistance among respiratory samples. Last, we developed yearly antibiograms for 
each facility between 2011 and 2014 to determine the hypothetical recommended 
use of broad spectrum antibiotics for each HAP patient based upon the ATS/IDSA 
provided thresholds. 
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Statistical Analysis
To assess the ATS/IDSA guidelines’ ability to accurately identify patients at 
risk for resistant pathogens, we examined the alignment between the 
recommendation for broad-spectrum antimicrobials and the recovery of relevant 
pathogens. In our analysis we evaluated both the providers’ behavior and the 
performance characteristics of the guidelines. We calculated provider sensitivity, 
defined as the proportion of admissions with positive cultures for MRSA or R-GNR 
that received an anti-MRSA drug or >1 anti-pseudomonal, and also the sensitivity of
the guidelines, defined as the proportion of cultures positive for a resistant 
pathogen that would be recommended to receive broad spectrum treatment. 
Similarly, we calculated provider specificity (the proportion of admissions without a 
resistant infection on cultures that did not receive empiric treatment for resistance) 
and guideline specificity (those lacking positive cultures that would not be 
recommended to receive treatment for resistance by the guidelines). We calculated 
the potential overtreatment and undertreatment of those with HAP if guideline 
recommendations were followed. Potential overtreatment was defined as the 
proportion of all patients who had negative cultures but were treated. Potential 
undertreatment was defined as the proportion of all patients who had positive 
cultures but were not treated. We then completed both a univariable and 
multivariable regression analysis to determine the predictive ability of the provided 
thresholds and patient characteristics thought to confer increased risk of resistance 
for HAP. Patient characteristics included: IV antibiotics in the previous 90 days, 
mechanical ventilation in the 48 hours prior to admission, and pressor order.(4-6, 
17, 18)  
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In our sensitivity analysis among all patients with a secondary diagnosis of 
pneumonia who did receive antibiotics or cultures in the initial 48 hours, we 
measured the rate of MRSA and R-GNR detection and estimated the empiric use of 
broad spectrum antibiotics if guideline recommendations were followed.
All statistical analyses were performed using STATA, Version 12.0 (StataCorp,
College Station, TX) and R (http://cran.r-project.org). The study was conducted with 
approval from the University of Utah Institutional Review Board and the Salt Lake 
City VA Human Research Protection Program. 
 
RESULTS:
Patient characteristics, antimicrobial coverage, and culture and detection
Of a total of 1.8 million hospitalizations at 113 facilities over three years, 
76,227 (4.23%) hospitalizations had a secondary diagnosis of pneumonia. After 
exclusion of those admitted for respiratory distress or sepsis, and subsequently 
those who received antibiotics or cultures in the first 48 hours of admission, the 
remaining 3,562 (0.20%) met our criteria for HAP leading to an incidence rate of 3.7
HAPs per 10,000 hospital days in patients without initial infection on admission.  
Manual chart review (conducted by AB) to validate the precision of our definition of 
HAP patients found a positive predictive value of 92.00%. Among the 3,562 
hospitalizations, median patient age was 69 years (mean 71, interquartile range 64-
79), and median length of stay was 16 days (mean 22 days, interquartile range 10-
26 days). Two-thousand, six-hundred and seventy-six (75.13%) of the admissions 
were to a medical service and 885 (24.85%) were to a surgical service. See Table 1 
for associated comorbidities. Seven-hundred and sixty-four (21.45%) patients spent 
at least one day in the intensive care unit (ICU) during their admission, 72 patients 
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(2.02%) had an order for vasopressors, and 94 patients (2.64%) received 
mechanical ventilation in the 48 hours prior to the HAP episode. Five-hundred and 
seventy-nine (16.25%) patients died within 30 days of their admission. Regarding 
cultures: 3,042 (85.40%) had blood cultures, 1,761 (49.44%) had respiratory 
cultures, and 1,447 (40.62%) had both. Of those patients mechanically ventilated, 
78 (82.98%) had respiratory cultures obtained. MRSA was detected by culture in 
184 patients (5.17%) and R-GNR were detected in 82 patients (2.30%) despite 
positive blood or respiratory cultures in 1,199 (33.66%) patients. (Table 1)  The 
most common pathogens identified were S. aureus, P. aeruginosa and Klebsiella. 
(Table E1) 
Antibiogram Feasibility and Utility
Among 113 VAMCs, we found 84 (74.34%) could generate annual, facility 
wide, Staphylococcus aureus methicillin antibiograms from all hospital cultures 
according to Clinical and Laboratory Standards Institute guidelines.(16) However, 
only 16 (14.16%) could generate antibiograms for MRSA from respiratory samples. 
For the ICUs, 17 (15.04%) could generate MRSA antibiograms and 68 (60.18%) 
could generate GNR antibiograms from all cultures though when limited to 
respiratory cultures only 2 (1.77%) could generate antibiograms for MRSA and 14 
(12.39%) for GNR resistance. When evaluating the prevalence of resistance 
between 2014 and 2017 among all centers we found the median facility-level 
prevalence of MRSA was 49% (interquartile range=44-54%) and the median R-GNR 
prevalence was 6.7% (interquartile range=4.3-9.3%). Almost all VAMCs (112, 
99.12%) had a prevalence of MRSA greater than 20%. For resistant GNR, the 
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prevalence among ICU’s was much more varied though the majority had a 
prevalence of resistance to piperacillin-tazobactam less than 20% (Figure 2).
Predictive performance of ATS/IDSA thresholds and patient characteristics for 
resistant infection
Among patients with HAP, 2,010 (56.43%) were empirically treated for MRSA 
and 809 (22.71%) were empirically treated for R-GNR with two or more anti-
pseudomonals. The sensitivity and specificity of the clinician’s empiric MRSA 
treatment was 69% (95% confidence interval [CI], 61.47 – 75.94%) and 39% (95% 
CI, 37.32 – 40.78%) respectively. For R-GNR, the sensitivity and specificity of 
clinicians’ empiric treatment was 38% (95% CI, 26.36 – 49.70%) and 76% (95% CI, 
74.04 – 77.04%) respectively. Using the ATS/IDSA specified threshold, we found that
3,561 (99.97%) of HAP patients were admitted to facilities with >20% prevalence of 
resistance so that all but one patient would be recommended to have coverage for 
MRSA by the guidelines, though only 184 patients (5.17%) grew MRSA on relevant 
cultures. The sensitivity of this treatment threshold was 100% (95% CI, 98.02% - 
100.00%) and the specificity was 0.03% (95% CI, 0.00% - 0.16%). This indicates 
that 94.81% (95% CI, 94.02 - 95.50%) of patients would be potentially overtreated 
using the 20% threshold for empiric coverage and no patients would be 
undertreated for MRSA. When incorporating the ATS/IDSA patients characteristics 
including intravenous antibiotics within the past 90 days, shock and ventilator 
requirement at time of HAP all patients but one would be recommended to receive 
empiric MRSA coverage, and 778 (21.84%) patients would be recommended to have
R-GNR coverage with 2 anti-pseudomonal agents. By univariable and multivariable 
analysis we did not find a MRSA prevalence of ≥ 20% or mechanical ventilation to 
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be significantly associated with an increased rate of MRSA detection (threshold 
p<0.05). We did find orders for vasopressors (odds ratio [OR], 3.89; 95% CI, 1.17 – 
12.91, p = 0.03) and IV antibiotics in the last 90 days (OR, 1.98; 95% CI, 1.03 - 3.81,
p = 0.04) to be associated with an increased risk of MRSA detection. For R-GNR we 
did not find an association between increased risk of resistant infection and IV 
antibiotics in the last 90 days or vasopressor order. However, we did find 
mechanical ventilation to be associated with increased risk of culture-proven R-GNR
infection (OR 4.37; 95% CI, 1.52-12.57, p = 0.01). (Table 2)
Sensitivity Analysis
Among all patients with a secondary pneumonia without a principal diagnosis 
of respiratory distress or sepsis (31,560 patients), we found 27,024 (85.63%) were 
admitted to a medical service, 4,500 (14.26%) were admitted to a surgical service, 
and 36 patients (0.11%) were admitted to non-medical and non-surgical services. 
Six-hundred and six patients (1.92%) grew MRSA on relevant cultures and 272 
patients (0.86%)  grew R-GNR. The most common pathogens identified were S. 
aureus, P. aeruginosa and Klebsiella spp. (Table E2) Using the ATS/IDSA specified 
threshold for anti-MRSA therapy, we found that 31,516 patients (99.86%) would be 
recommended to receive anti-MRSA treatment. When including those who had 
received antibiotics in the past 90 days this increased the number indicated to have
anti-MRSA therapy to 31,520 (99.87%). Additionally, when evaluating the number of
patients recommended to receive dual anti-pseudomonal therapy from our larger 
cohort, we found that 23,724 (75.17%) received antibiotics on admission which 
would lead to the recommendation for dual anti-pseudomonals at time of HAP. 
Furthermore, when incorporating patients characteristics including shock and 
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ventilator requirement at time of HAP an additional 139 patients would be 
recommend to receive dual anti-pseudomonal therapy indicating that a total of 
23,863 (75.61%) would be recommended to have dual anti-pseudomonal coverage. 
DISCUSSION:
Our study is the first to examine the potential consequences of the ATS/IDSA 
guidelines using resistance prevalence thresholds to help guide antimicrobial 
decisions and their performance as tools to identify resistant infections in a large 
multicenter study. We found the number of patients treated with antibiotics against 
MDR pathogens far exceeded the number of cultures found to display antibiotic 
resistance. Additionally, when applying the guideline-recommended prevalence of 
resistance thresholds at which broad-spectrum coverage should be initiated, we 
found this would substantially increase the use of anti-MRSA antimicrobials 
compared to clinical practice without improved predictive performance had the 
guidelines been in place historically. The reason for this is likely multifactorial. It 
may in part be due to the inherent difficulty in a universal threshold when there is 
overall low prevalence of resistant infection. Additionally, this finding may 
emphasize that the risk of infection with a resistant pathogen is more dependent on
the particular pathogen in concert with a susceptible host. Factors influencing host 
susceptibility may include underlying lung disease, history or resistant infection, 
history of antimicrobial use and ventilator associated injury. 
The rate of detection of resistant organisms in our population is similar to 
rates found in the VA system in HCAP albeit lower than that described by Chung et 
al. in their cohort from Asia, though the most common pathogens were similar.(19, 
20) Our rates of resistance were more consistent with those found by Kollef et al. 
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potentially due to more similar populations, severity of illness and sampling 
practices.(21) Our findings are in concert with Ekren et al. who also found very high 
sensitivity for the given resistant risk factors and very poor specificity leading to 
significant potential overtreatment.(22) Additionally, the risk factors we found to be 
significantly associated with resistant infection were consistent with the findings of 
Martin-Loeches et al (i.e., including IV antibiotics in the past 90 days, shock and 
mechanical ventilation). (23)
Our study has several limitations. We used administrative data that relied 
upon principal diagnostic codes to identify cases of pneumonia and therefore may 
not have captured all HAPs due to inconsistent diagnostic coding practices or 
missed diagnosis. Additionally, our detection rates of resistant infection were limited
by the culturing practices of the providers. While overall there was a high rate of 
blood cultures, respiratory cultures were obtained in only about half of admissions. 
A larger percentage of patients mechanically ventilated had respiratory cultures 
obtained though overall the number mechanically ventilated in the 48 hours prior to
their infection was small (2.64%). We defined Gram-negative resistance as 
resistance to piperacillin-tazobactam for purposes of feasibility, because it is a 
common treatment for HAP and a primary agent recommend by the ATS/IDSA for 
HAP. Additionally, it is the most common anti-pseudomonal that was administered 
for CAP across the VA after fluoroquinolones.(8) However, because hospitals may 
have different antimicrobial practices this may limit the generalizability of our 
results. Our primary analysis was limited to patients who were admitted to the 
hospital without receipt of antibiotics or cultures upon admission in order to ensure 
that we captured new diagnoses of pneumonia (rather than a late diagnosis of 
community acquired pneumonia) and no additional infectious diseases that could 
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complicate the antibiotic choices. As this approach substantially reduced our 
sample size and potentially skewed our population to a healthier subset of patients, 
this limits the generalizability of our findings. However, we also completed a 
sensitivity analysis of all patients with secondary diagnosis of pneumonia, including 
those who received antibiotics and cultures within the first 48 hours. This cohort 
demonstrated lower rates of detected resistance, but suggested similar 
consequences of guidelines on treatment: all members would be recommended to 
receive anti-MRSA therapy and 75% would be recommended to receive dual anti-
pseudomonals given the guideline recommendations. Furthermore, given that the 
facility-level prevalence of MRSA in S. aureus antibiograms was >20% in almost all 
facilities over the time period evaluated, nearly universal anti-MRSA coverage would
be recommended for HAP regardless of admission type. Therefore, despite the 
restricted nature of our primary HAP cohort our study suggests that antibiogram-
guided therapy at the recommended thresholds would substantially increase 
unnecessary broad-spectrum antibiotic use for HAP in more generalized patient 
populations. Last, our study included secondary diagnoses of pneumonia, not only 
culture-confirmed cases. Because of this, we likely included patients who lacked 
true infection. Unfortunately, this is the clinical reality of pneumonia: there is no 
gold standard for the diagnosis of pneumonia and cultures are rarely revealing. Our 
chart review did, however, demonstrate a relatively high positive predictive value in
our cohort of interest. 
Recommendations for the optimal empiric treatment of HAP must balance the
need for effective patient treatment while minimizing unwarranted broad-spectrum 
antibiotic use. In order to achieve this, previous guidelines have emphasized 
limiting broad-spectrum use to those with either increased risk for resistant 
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infection due to patient characteristics or the patient’s environmental exposure to 
resistant pathogens. At present, the evidence behind using a single antibiogram-
based threshold to guide broad-spectrum antibiotic use is limited, making universal 
recommendations difficult. Focusing on refining our understanding of host 
susceptibility and host-pathogen interactions (and thus on patient-specific rather 
than population-level risk of infection by resistant pathogens), while working to 
establish improved rapid diagnostic testing and resistance prediction are the most 
promising pathways for adequate empiric treatment. In the meantime, clinicians 
and stewardship programs will be wise to heed the guideline’s admonition to use 
local data to anticipate potential impact and inform local adaptation of guideline 
implementation. Future research evaluating the comparative benefits and harms of 
initial broad spectrum treatment will be instrumental to evaluating the risk 
associated with different empiric strategies.
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Figure 1. Study population
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Table 1. Demographics and clinical characteristics of patients
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Figure 2.  Prevalence of resistance in antibiograms at 113 VAMCs from all hospital 
cultures
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Table 2. Multivariable Model for Resistant Infection
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Table E1.
Organisms Recovered from 3,562 Patients with HAP
Organism Sample Type Number of positive cultures
Proportion
Resistant
Staphylococcus aureus sputum 323 0.45
Pseudomonas aeruginosa sputum 184 0.11
Genus Klebsiella sputum 154 0.14
Escherichia coli sputum 106 0.06
Staphylococcus aureus blood 100 0.45
Genus Enterobacter sputum 80 0.24
Genus Serratia sputum 40 0.15
Genus Klebsiella blood 38 0.05
Escherichia coli blood 37 0.03
Genus Stenotrophomonas sputum 32 0
Genus Proteus sputum 31 0
Genus Citrobacter sputum 21 0.05
Genus Acinetobacter sputum 12 0
Genus Enterobacter blood 12 0.25
Pseudomonas aeruginosa blood 12 0.25
Genus Proteus blood <10 0
Genus Serratia blood <10 0
Genus Stenotrophomonas blood <10 0
Genus Acinetobacter blood <10 0.2
Genus Citrobacter blood <10 0
Genus Morganella sputum <10 0
Raoultella planticola sputum <10 0
Pantoea agglomerans sputum <10 0.5
Raoultella ornithinolytica sputum <10 0
Genus Providencia sputum <10 0
Hafnia alvei sputum <10 1
Family 
Enterobacteriaceae sputum <10 0
Table E2. 
Organisms Recovered from 31,560 Patients with Secondary Pneumonia
Organism Sample Type Number of positive cultures Proportion Resistant
438
439
440
441
442
Staphylococcus aureus sputum 960 0.54
Pseudomonas aeruginosa sputum 646 0.11
Genus Klebsiella sputum 475 0.16
Escherichia coli sputum 304 0.13
Genus Enterobacter sputum 244 0.26
Staphylococcus aureus blood 198 0.48
Genus Stenotrophomonas sputum 145 0.02
Genus Serratia sputum 132 0.10
Genus Klebsiella blood 97 0.15
Genus Proteus sputum 83 0.02
Escherichia coli blood 82 0.04
Genus Citrobacter sputum 64 0.11
Genus Acinetobacter sputum 63 0.11
Pseudomonas aeruginosa blood 45 0.09
Genus Enterobacter blood 30 0.27
Genus Serratia blood 18 0.00
Genus Proteus blood 14 0.00
Genus Acinetobacter blood 12 0.08
Genus Providencia sputum 12 0.42
Genus Morganella sputum 11 0.00
Genus Stenotrophomonas blood <10 0.00
Genus Citrobacter blood <10 0.17
Raoultella planticola sputum <10 0.00
Hafnia alvei sputum <10 0.20
Pantoea agglomerans sputum <10 0.33
Genus Providencia blood <10 0.33
Genus Morganella blood <10 0.00
Family Enterobacteriaceae sputum <10 0.00
Cronobacter sakazakii sputum <10 0.00
Kluyvera species sputum <10 0.00
Raoultella ornithinolytica sputum <10 0.00
Pantoea species blood <10 0.00
Pantoea species sputum <10 0.00
Yokenella regensburgei sputum <10 0.00
Leclercia adecarboxylata sputum <10 0.00
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